ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.

Bruce Ac Cree et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.